BEDFORD, Mass., Jul. 14, 2004 /PRNewswire-FirstCall/ -- Hologic, Inc. (NASDAQ: HOLX), a leading provider of women's diagnostic imaging systems and state-of- the-art digital imaging systems, today announced they have entered into a collaborative research agreement with the David Geffen School of Medicine at the University of California at Los Angeles (UCLA) to study a variety of advanced breast imaging applications.
Hologic and UCLA will collaborate on a number of research projects to assess current uses of breast imaging modalities and to explore potential methods for improved screening and diagnostic applications. The research will assess digital mammography workflow versus the conventional film method, the uses and efficiencies of a dedicated breast ultrasound system in a breast imaging practice, and the effectiveness of computer-aided-detection in breast MRI. Additional areas of research will focus on new mammography technologies that will undergo clinical testing and be evaluated for commercial release.
"Our relationship with UCLA holds great promise for the further development and evaluation of digital mammography and assessment of its relationship with other established and emerging breast imaging modalities," said Jack W. Cumming, Chairman and CEO for Hologic, Inc. "The emergence of digital mammography has created the need for specific research to support and strengthen its role as a viable and potentially better technology for the early detection of breast cancer, particularly when used in combination with complementary technologies. UCLA is a world-renowned research center and will be an excellent partner in this endeavor. We are excited about this research project, and believe collaborations of this type between universities and industry can be of significant benefit to patients."
At UCLA, the collaboration is headed by Dr. Lawrence Bassett, Managing Director and Dr. Dieter Enzmann, Chairman. Dr. Bassett is also a recognized researcher at UCLA's Jonsson Cancer Center. According to Dr. Bassett, "We are very eager to begin our research with Hologic. Their reputation as the leading provider of innovative breast imaging systems and the comprehensive portfolio of equipment that will be assessed under this agreement provides assurance that significant research to enable better patient outcomes will result from this collaboration. Our staff is dedicated to constantly searching for better breast cancer screening alternatives and we look forward to a long and successful collaboration with a group that shares this goal."
"Our collaboration with Hologic marks the beginning of a more comprehensive approach to breast imaging in the digital environment. We have high expectations of having a beneficial impact for women at risk for breast cancer" added Dr. Enzmann.
About Hologic Inc.
Hologic Inc. is a leading developer, manufacturer and supplier of medical imaging systems dedicated to serving the healthcare needs of women, and a leading developer of state-of-the-art digital imaging technology for general radiography and mammography applications. Hologic's core business units are focused on osteoporosis assessment, mammography and breast biopsy, direct-to- digital X-ray for general radiography applications and mini C-arm imaging for orthopedic applications.
About the David Geffen School of Medicine
In just over 50 years -- within the lifetimes of many of its original architects -- the David Geffen School of Medicine at UCLA has joined the ranks of the nation's elite medical schools. During a period of revolutionary change in biomedical research and patient care, the school quickly moved to the forefront of academic medicine and discovery. The medical school today has more than 2,000 full-time faculty members, almost 1,300 residents, more than 750 medical students and almost 400 Ph.D. candidates.
Forward Looking Disclaimer
This News Release contains forward-looking information that involves risks and uncertainties, including statements regarding Hologic's plans, goals, objectives, expectations, intentions and beliefs. Such statements include, without limitation, statements regarding: the goals, plans and focus for Hologic's and UCLA's collaborative efforts and the parties expectations regarding the results of those efforts. These forward-looking statements are subject to known and unknown risks and uncertainties that could cause actual results to differ materially from those anticipated. Factors that could cause actual results to materially differ include, without limitation: Hologic's and UCLA's limited experience in working together; Hologic's substantial dependence on the efforts of UCLA and its staff to make this relationship successful; uncertainties inherent in the development of new products and the enhancement of existing products, including technical and regulatory risks, cost overruns and delays; and the risk that newly introduced products may contain undetected errors or defects or otherwise not perform as anticipated. Other factors that could adversely affect Hologic's business and prospects are described in Hologic's filings with the Securities and Exchange Commission. Hologic expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in Hologic's expectations or any change in events, conditions or circumstances on which any such statement is based.
Contact: Glenn P. Muir Executive Vice President & CFO Hologic, Inc. (781) 999-7300 Frances Crecco Director, Investor Relations Hologic, Inc. (781) 999-7377
SOURCE: Hologic, Inc.
CONTACT: Glenn P. Muir, Executive Vice President & CFO, +1-781-999-7300,
or Frances Crecco, Director, Investor Relations of Hologic, Inc., +1-781-999-
Web site: http://www.hologic.com/